Lung cancer is one of the more prominent cancers known to the medical field, with non-small cell lung carcionma (NSCLC) being the most common. Calu-3 cells come from such a cancer, and are useful tools in medical research evaluating the effects of genetic modification on cell proliferation. With the proper reagents, transfected siRNA, DNA, and RNA sequences can affect cell functionality and lead to important results that inform preclinical testing and in vitro effects of gene therapies and drugs.
The Calu-3 cell line was derived from the carcinomatous lung tissue of a 25 year old Caucasian male suffering from adenocarcinoma. Before the cell line was established the patient had received therapy with bleomycin , cytoxan, and adriamycin. The tumorigenic, epithelial cells of the Calu-3 cell line are now used to produce a transfection host model for various types of lung cancer as well as other biomedical research. The Calu-3 transfection reagents established by Altogen Biosystems allow an intracellular delivery of pDNA, mRNA and siRNA and the recombinant protein expression desired in certain research. Calu-3 Transfection Reagent (Lung Carcinoma Cells, HTB-55)
Comments
Post a Comment